Back to Search Start Over

PROGRESSION FREE SURVIVAL AT 12 MONTHS AFTER FIRST-LINE THERAPY IS ASSOCIATED WITH FAVOURABLE OUTCOMES AFTER FIRST RELAPSE/PROGRESSION IN PERIPHERAL T-CELL LYMPHOMA